Scale -


  • Revenue is 14278 Rs Cr; Annual Growth is 17 %; Continuous Growth over 3 years; 5 Year CAGR is 16 %
  • Ebitda is 3976 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 16 %
  • PBT is 766 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Ebitda is 1056 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile
  • Quarterly Profit is 570 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile

Profitability -


  • PAT Margin is 13.49 %; Annual Decline is -18 %; Continuous Decline over 3 years

Return -


  • ROA is 6.81 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -19 %
  • ROE is 11.73 %; Continuous Decline over 3 years; 5 Year CAGR is -16 %
  • Asset Turnover is 51 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -15 %
  • ROCE is 14.32 %; 5 Year CAGR is -18 %

Efficiency -


  • Inventory Turnover Ratio is 6.74; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 80 %
  • Operating cash flow is 3121 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 36 %
  • Current Ratio is 1.07; Continuous Decline over 3 years; in Bottom Quartile
  • Quick Ratio is 0.74; Continuous Decline over 3 years; in Bottom Quartile

Solvancy -


  • Debt/Equity is 0.38; Annual Decline is -36 %; 5 Year CAGR is 28 %
  • Long term Debt is 2821 Rs Cr; Annual Decline is -49 %; in Top Quartile; 5 Year CAGR is 171 %
  • Contingent Liabilities is 9140 Rs Cr; Annual Growth is 72 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 156 %
  • Total Debt is 6204 Rs Cr; in Top Quartile; 5 Year CAGR is 63 %

Quality -


  • Operating cashflow/PAT is 162 %; Annual Growth is 34 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 26 %
  • Operating cashflow/ebitda is 78 %; in Top Quartile; 5 Year CAGR is 17 %
  • Change in Inventories/Total Expenses is 0 %; Annual Growth is 117 %; in Top Quartile
  • Current Tax/PAT is 30 %; Continuous Growth over 3 years

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Mankind Pharma Q2FY27 Results: Revenue up 17%, EBITDA margin hits 27.1%
Mankind Pharma Elevates Deepak Sharma to Senior General Manager & Head – L&D and Recruitment, India & International Business
Pink October: Mankind Pharma calls for greater awareness around breast cancer, early detection and timely treatment
Mankind Pharma promotes Aparajita Nandita Raychaudhuri to Sr. VP & Head of API Sales and Marketing
Mankind Pharma’s Q2 profit jumps 38% as revenue rises 17% to Rs 4,338 Cr
Mankind Pharma among 5 F&O stocks with a sharp rise in futures open interest
Mankind Pharma jumps 8% on Q2 earnings beat but here's why analysts remain concerned
Mankind Pharma Ltd Reports Very Positive Quarterly Financial Performance Amid Market Volatility
Mankind Pharma Ltd Sees Robust Trading Activity Amid Mid-Cap Rally
Mankind Pharma Ltd Sees Sharp Open Interest Surge Amidst Strong Price Momentum
Mankind Pharma Q2 FY27 Profit Jumps 38% to ?716 Crore as Chronic Therapies Drive Domestic Growth
Mankind Pharma Q2 PAT jumps over 37% to Rs 716 crore
Mankind Pharma Q2 Profit Jumps 39% to Rs 711 Crore on Strong Cardiac, Diabetes Drug Sales
Mankind Pharma Q2 Review: Export Momentum Continues; Systematix Maintains 'Hold'; Check Target Price
Mankind Pharma Q2 Review: Jefferies, Kotak Retain Buy After Strong Earnings. Check Target Prices
Mankind Pharma Sees Sharp Open Interest Surge Amid Mixed Technical Signals
Mankind Pharma shares jump 8%: What brokerages say after Q2 results
Mankind Pharma Shares Jump Nearly 8% After Q2 Profit Rises 39%
Mankind Pharma shares surge over 8% on strong Q2 earnings show; further growth potential ahead?
Mankind Pharma soars 11% in 2 days on strong Q2 earnings; brokerages upbeat
Mankind Pharma stock surges 9% after strong Q2 results; Kotak sees big upside, other brokerages cautious
Mankind Pharma, AIOS And EBAI Join Hands To Promote Eye Health Awareness
Mankind Pharma’s employee costs jump 15% to Rs 949 crore; field-force productivity improves
MANKIND: Chronic expansion and ACTx’s in vivo CAR-T pipeline anchor the next growth phase
MANKIND: FY26 growth priorities expand into specialty care and next-generation CAR-T
Trade Spotlight: How should you trade BSE, Mankind Pharma, Bajaj Finserv, Bharti Airtel, Zydus...
Aparajita Nandita Raychaudhuri Elevated to Senior Vice President and Head – API Sales & Marketing at Mankind Pharma
Condom selling company Mankind Pharma clocks over ?716 cr profit: Revenue increases to ?4,330 cr in Sept 20...
Earnings call transcript: Mankind Pharma posts strong Q2 2026 growth as stock rises
Earnings Central: Ather Energy turns profitable, Tata Consumer and Mankind Pharma beat Street
Mankind Pharma (MANKIND.NS) Jumps 4.49% to ?2312.0 — Bulls Now Test ?2427.6 Resistance
Mankind Pharma (NSE:MANKIND) Approves Amalgamation of Two Subsidiaries
Mankind Pharma Jumps 5% to Day High as Q2 Profit Rises 39%
Mankind Pharma Limited Reports Unaudited Standalone and Consolidated Financial Results for Q2 and H1 FY 2026-27
Mankind Pharma Ltd (NSE:MANKIND) (Q2 2027) Earnings Call Highlights: Revenue Jumps 17% as ...
Mankind Pharma Q2 FY27 Results: Revenue Up 17%, PAT Rises 38%
Mankind Pharma Q2 FY27 slides: margins expand as chronic therapies drive growth By Investing.com
Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business
Mankind Pharma Q2 profit jumps 38 per cent to Rs 716 crore
Mankind Pharma Q2 profit jumps 39% to ?712 crore as revenue rises 17%
Mankind Pharma Q2 Profit Jumps 39% To Rs 712 Cr; Board Clears Subsidiary Mergers
Mankind Pharma Q2 results: Profit rises 39% YoY to ?711 crore as operating margins improve 300 basis points
Mankind Pharma Q2 Results: Revenue at Rs 4,433 crore, Profit beats estimates
Mankind Pharma releases audio recording of Q2FY27 earnings call
Mankind Pharma shares key business developments from Q2 & H1 of FY27
Mankind Pharma's quarterly profit jumps 39% on strong chronic drug demand
Mankind Pharma Ltd. Estimates – NSE:MANKIND
Delhi HC Settles Mankind Pharma Trademark Suit as Caremankind Hospital Agrees to Change Name
Mankind Pharma Enters CAR-T Therapy with Armed Cell Acquisition
Mankind acquires majority stake in Belgium-based Armed Cell Therapeutics
Mankind Pharma plans EUR 45 million infusion into Dutch unit and majority stake in ACTx
Mankind Pharma to Acquire 70% Stake in Armed Cell Therapeutics for Rs 511.4 Crore
Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx
Mankind Pharma to buy Belgian biotech firm for cancer-care innovation
Mankind Pharma to acquire 70% in Belgian biotech firm for €48 million
Mankind Pharma, Zydus Lifesciences among top losers, fall up to 3% after Supreme Court asks Centre to...
Stock of the day
Mankind Pharma Moves Delhi HC Against Kind Marks, Court Restrains Florakind, Coskind, 4 Others
Delhi High Court protects Mankind Pharma’s “KIND” formative marks against deceptively similar pharmaceutical marks